Objective: To assess the efficacy and toxicity of the Lupus-Cruces Nephritis (LCN) protocol compared with standard of care (SOC) with cyclophosphamide (CYC) or mycophenolate in patients with lupus nephritis (LN) during an extended follow-up time up to 10 years. Methods: Patients with biopsy-proven class III, IV or V LN treated with LCN were compared with SOC. Patients in the LCN were treated with a CYC plus repeated methylprednisolone pulse-based regimen. The achievement of complete renal response (CRR) and the progression to chronic kidney disease (CKD) were the two main outcomes. Glucocorticoid (GC)-related toxicity, major infections and damage accrual were also analysed. A propensity score (PS)-adjusted multivariate analysis was used to overcome the confounding-by-indication bias. Results: 147 patients were included in this study (47 LCN and 100 SOC). CRR at 12 months was 85% vs 44%, respectively (p<0.001). Eventually, 96% patients in the LCN group achieved CRR vs 74% patients in the SOC (p=0.002). In the multivariate PS-adjusted Cox model, LCN patients were more likely to eventually achieve CRR (PS-adjusted HR 3.5, 95% CI 2.2 to 5.5, p<0.001). The risk of progression to CKD was lower in LCN patients (PS-adjusted HR 0.3, 95% CI 0.11 to 0.82, p=0.019). The risks of GC-induced toxicity, renal or GC-related damage accrual and major infections were also lower in the LCN group: adjusted HR 0.09, 95% CI 0.02 to 0.39; PS-adjusted HR 0.14, 95% CI 0.04 to 0.4; PS-adjusted HR 0.2, 95% CI 0.046 to 0.95; respectively. Conclusions: This study confirms the LCN protocol as an effective and safe, in addition to widely available and affordable, regimen for the induction therapy of LN.
Objective: To assess the efficacy of the Lupus-Cruces Nephritis (LCN) protocol vs standard of care (SOC) in achieving complete vrenal response (CRR) among different subpopulations and clinical clusters of patients with LN. Methods: This was an observational comparative study with clinical care data of patients from the Lupus-Cruces, historic Lupus-Cruces and Lupus-Bordeaux cohorts. Different prognostic factors were obtained from previous studies and analysed in both LCN and SOC groups. Three different clinical clusters of patients were identified using a two-way clustering analysis. A multivariate propensity score (PS) adjusted analysis and Cox proportional hazards analysis were performed comparing both therapeutic schemes in the different identified subpopulations and clusters. Results: Within the cohort of 147 patients, those receiving the LCN protocol (40/47, 85%) were more likely to achieve CRR at 12 months than patients receiving the SOC (44/100, 44%). This was consistent across all prognostic subpopulations. The PS-adjusted logistic regression by subgroups confirmed these results. Three different clusters (named C1, C2 and C3) were identified. Both the univariate and the PS-adjusted Cox regression analysis for CRR at any time confirmed the higher likelihood of achieving CRR of patients treated with the LCN protocol in the three clusters: C1, hazard ratio (HR) 10.7 (95% CI 1.65–69.6, P = 0.013); C2, HR 2.2 (95% CI 1.16–4.1, P = 0.016); C3, HR 6.1 (95% CI 2.99–12.51, P < 0.001). Conclusion: The LCN protocol was superior to the SOC schemes in achieving CRR in patients with LN across different subpopulations and clinical clusters.
Objective: To analyse the achievement and long-term clinical impact of different types of renal response (RR) in 147 patients with lupus nephritis (LN). Methods: Four mutually exclusive levels of proteinuria at 12 months were defined: DR (deep remission, Pr/Cr ≤0.15 g/g), CRR 0.15-0.5 (complete renal response with Pr/Cr >0.15-0.5 g/g), RR 0.5-0.7 (renal response with Pr/Cr >0.5-0.7 g/g) and NR (no response, Pr/Cr >0.7 g/g). Early CRR (Pr/Cr ≤0.5 g/g at 6 months) was also studied. The occurrence of long-term renal outcomes (CKD and ESKD), renal or glucocorticoid (GC)-related damage and relapses was analysed. Multivariate Cox analysis were adjusted by clinical clusters of LN and antiproteinuric drugs use. Results: 23% achieved DR, 34% CRR 0.15-0.5, 7.5% RR 0.5-0.7 and 35% NR. Evolution to CKD increased with growing levels of proteinuria (p = 0.002). No patients with DR or CRR 0.15-0.5 progressed towards ESKD. In the Cox models, patients in the DR and CRR 0.15-0.5, but not those in the RR 0.5-0.7 group, were less likely to evolve to CKD and to accrue damage compared to NR. Patients with early CRR were more likely to achieve DR and less likely to develop CKD (8% vs 31.5%, p = 0.001). No effects of proteinuria levels on relapses were seen. Conclusion: CRR with Pr/Cr ≤0.5 at 12 months is a feasible good prognostic target, whilst the extension towards Pr/Cr ≤0.7 includes patients with more adverse prognosis. DR is a more difficult but ideal objective. The achievement of early CRR at 6 months should be considered a desirable intermediate goal.